TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02071836

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Study: NCT04612517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP7570
Description: Each subject will be randomly allocated to multiple doses of ZP7570 at one of four dose levels in each cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; corresponding volume
Study: NCT04283916

Intervention type: DRUG
Intervention: Botulinum Toxins
Description: Botulinum toxin injection to abdominal wall
Study: NCT02981628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV or SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Imaging
Description: Undergo imaging

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study: NCT03267420

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BpTRU First, Unattended Omron Second
Description: Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Unattended Omron First, BpTRU Second
Description: Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Partially Attended Omron First, Unattended Omron Second
Description: Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.~Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted.
Study: NCT03866915

Intervention type: DIAGNOSTIC_TEST
Intervention: Aortic pulse wave velocity measurement
Description: Aortic pulse pulse wave velocity (AoPWV) measured by photoplethysmography

Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minutes walking test
Description: This test is performed routinely in the pre-rehabilitation units or in external anesthesiology consultations during the preoperative visit. In essence, it consists in measuring the maximum distance the patient is able to walk in 6 minutes, in a short walk in a corridor, simultaneously assessing the heart rate, oxygen saturation and the degree of dyspnea. In general, healthy people can walk between 400 and 700 meters in 6 minutes, depending on age, height and sex.
Study: NCT00593502

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The dosage of placebo will be similar to the active drug
Study: NCT03238976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature sounds
Description: Nature sounds will be played for patients in the nature sounds exposure group.
Study: NCT02981628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV or IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT02071836

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study: NCT04756245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within virtual reality software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both virtual reality and real-world physical activities.
Study: NCT03725852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1205
Description: GLPG1205 will be provided as an oral hard gelatin capsule.
Study: NCT03609424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001, Imatinib
Description: -Phase Ib part~: The standard 3+3 dose escalation scheme will be applied. DLTs will be evaluated during the first cycle (4 weeks).~PDR001 400mg, every 4 weeks, IV~Imatinib dose level -1 : 200mg, PO, QD Imatinib dose level 1 : 300mg, PO, QD Imatinib dose level 2 : 400mg, PO, QD~-Phase II part~* Recommended dose defined in phase Ib part will be tested
Study: NCT01820000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging with MRI scans
Description: Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
Study: NCT00506142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo® (vincristine sulfate liposomes injection)
Description: Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marqibo® (vincristine sulfate liposomes injection)
Description: Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.~Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week.
Study: NCT02345239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: proton pump inhibitor
Study: NCT02213250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BENEFIX
Description: Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
Study: NCT04756245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Conference
Description: Participants in this arm participate in 4 group-based behavioral counseling sessions plus 8 one-on-one coaching session within video conference software. Participants aim to engage in approximately 150 minutes per week of moderate-to-vigorous activity, with options including both streaming video and real-world physical activities.
Study: NCT01689090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COX inhibitor
Description: Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
Study: NCT03725852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GLPG1205 matching placebo will be provided as an oral hard gelatin capsule.
Study: NCT04552002

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic group
Description: Probiotics and prebiotics
Study: NCT03112876

Intervention type: OTHER
Intervention: Skin Surface Lipid Collection and Skin Barrier Function
Description: All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.

Intervention type: OTHER
Intervention: Skin Surface Lipid Collection and Skin Barrier Function
Description: All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.

Intervention type: OTHER
Intervention: Skin Surface Lipid Collection and Skin Barrier Function
Description: All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.

Intervention type: OTHER
Intervention: Skin Surface Lipid Collection and Skin Barrier Function
Description: All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.

Intervention type: OTHER
Intervention: Skin Surface Lipid Collection and Skin Barrier Function
Description: All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
Study: NCT00182143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMWH (Fragmin, dalteparin)
Description: Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: 5000 IU BID
Study: NCT01689090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COX inhibitor
Description: Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-NG-monomethyl arginine citrate
Description: Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
Study: NCT02300233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Description: 300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Description: 300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
Study: NCT03745950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib Oral Capsule
Description: - Olaparib will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: - Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
Study: NCT04326452

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bidirectional oxygenation mouthpiece
Description: Use of our bidirectional oxygenation mouthpiece with conventional oxygen support.
Study: NCT04089514

Intervention type: DRUG
Intervention: Adalimumab
Description: Administered as specified in the treatment arm
Study: NCT03212352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: Regular treatment with Misoprostol 800 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Regular treatment with Misoprostol 800 mcg.
Study: NCT04670809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine Butyrate Injection
Description: Initiate the intravenous infusion of Clevidipine Butyrate Injection at 2 mg/hour. The dose should be doubled every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 32 mg/hour. The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ncardipine Hydrochloride Injection
Description: Dilute the Ncardipine Hydrochloride Injection to 0.1mg/ml. Initiate the intravenous infusion at 0.5μg/(kg•min). A 0.5-1μg/(kg•min) dose should be added every 3 minutes in the first 30 minutes if the desired blood pressure reduction (≥15% and ≤25%) is not achieved and the maximum dose is 6μg/(kg•min). The infusion duration should be at least 12 hours and less than 72 hours. Oral antihypertensive drugs should be given at about 2 hours before stopping infusion.
Study: NCT02746302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00427193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction (CR)
Description: Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
Study: NCT01689090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-NG-monomethyl arginine citrate
Description: Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COX inhibitor + L-NG-monomethyl arginine citrate
Description: Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COX inhibitor + L-NG-monomethyl arginine citrate
Description: Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
Study: NCT03675581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon
Description: fixed sequence trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: fixed sequence trial
Study: NCT03557008

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: A 1.0 milliliter (mL) dose of Imovax® will be given to participants on Day 0 and Day 28 of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Flagyl taken by mouth three times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 125 mg of Vancocin taken by mouth four times a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neomycin Sulfate
Description: The antibiotic regimen will be given for five days beginning 3 days prior to vaccination, on the vaccination day, and one day after vaccination for a total for 5. The regimen will include 500 milligrams (mg) of Neomycin sulfate taken by mouth three times a day.
Study: NCT00731497

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solar Water Disinfection (SODIS)
Description: Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
Study: NCT00269789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritalin
Study: NCT00427193

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants continue their current diet for 24 months
Study: NCT00269789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS Methylphenidate HCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00296361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: immunosuppression
Study: NCT00748631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon kyphoplasty
Description: A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
Study: NCT00818194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release tacrolimus
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended release tacrolimus
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A microemulsion
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A microemulsion
Description: oral
Study: NCT04124627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance in addition to radiographic guidance
Description: Patients that will be operated will receive ultrasound guidance in addition to radiographic guidance, that is gold standard
Study: NCT03001843

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pain scale
Description: 0-10 pain scale. 0 = no pain and 10 = worst pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pain scale
Description: 0-10 pain scale. 0 = no pain and 10 = worst pain
Study: NCT02205502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT03858218

Intervention type: OTHER
Intervention: questionnaires set
Description: questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)

Intervention type: OTHER
Intervention: questionnaires set
Description: questionnaires set: The Chinese version of the Pittsburgh Sleep Quality Index (PSQI)+The Chinese version of the Center for Epidemiologic Studies Depression Scale for Children (CES-DC)+ The Chinese version of the Pediatric Quality of Life Inventory 4.0 Generic Core Scale (PedsQL 4.0)
Study: NCT03218891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:~* 5 minutes warm up~* 30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;~* 10 minutes of localized exercises;~* 5 minutes of relaxation.
Study: NCT01564459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6096
Description: MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MK-6096
Description: MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching compressed tablets, taken once daily at bedtime for 14 days.
Study: NCT02818387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
Study: NCT01488942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: monetary reinforcer
Description: The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
Study: NCT01313520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion